|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
|
| Published Date:
May 2009
Published By:
Datamonitor
Page Count:
264
Order Code:
R313-51599
|
|
|
|
With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
Scope- Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
- R&D Insight from Big Pharma industry executives
- Analysis into Pharma's evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
- Case studies of innovative strategies used to maximize R&D productivity
Highlights- GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentech's pipeline grew the most in terms of percentage points, almost doubling (up 95%).
- Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharma's shift towards niche markets and personalized medicines.
- The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.
Reasons to Purchase- Identify R&D trends in today's pharmaceutical market, and how these affect productivity and return on investment
- Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
- Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
